The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C08 | Calcium channel blockers | |
3
|
C08D | Selective calcium channel blockers with direct cardiac effects | |
4
|
C08DA | Phenylalkylamine derivatives | |
5
|
C08DA01 | Verapamil |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 0.24 g | |
| PAREN | Parenteral | 0.24 g |
| Active Ingredient |
|---|
|
Verapamil inhibits the transmembrane influx of calcium ions into the heart and vascular smooth muscle cell. The myocardial oxygen demand is lowered directly as a result of the effect on the energy consuming metabolic processes of the myocardial cell and indirectly due to a reduction of the afterload. Due to its effect on coronary vascular smooth muscle, verapamil enhances myocardial blood flow, even in post‐stenotic areas, and relieves coronary spasms. These properties contribute to the anti‐ischaemic and antianginal efficacy of verapamil in all types of coronary artery disease. |
| Document | Type | Information Source | |
|---|---|---|---|
| AKILEN Film-coated tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| ISOPTIN Film‐coated tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| ISOPTIN Solution for injection / infusion | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| SECURON Solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| SECURON SR Modified-release tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.